Historical Prototype: Physostigmine
Physostigmine is an alkaloid isolated from the plant Physostigma venenosum (Calabar beans). As a tertiary amine, it readily crosses the blood-brain barrier (BBB) and exerts pronounced central effects. At high concentrations, the drug can not only increase neurotransmitter accumulation but also directly stimulate cholinergic receptors.
Historically, physostigmine was used in two main areas:
- Toxicology: Served as a classical antidote for central nervous system-penetrating anticholinergic poisonings (specifically, Atropa belladonna and atropine intoxication).
- Ophthalmology: Used to manage acute angle-closure glaucoma attacks. By inducing miosis (pupillary constriction), the drug effectively facilitates the outflow of aqueous humor, surpassing pilocarpine in potency. However, its use was limited by a severe drawback: powerful contraction of the iris provokes intense pain in the eyes and supraorbital ridges.
Physostigmine served as the starting point for developing an entire class of drugs for neurodegenerative diseases, although it is no longer used for dementia due to its very short duration of action and numerous peripheral adverse effects.
Pathophysiology and Treatment of Alzheimer's Disease
The pathogenesis of Alzheimer's disease is based on progressive atrophy of neurons in the cerebral cortex and subcortical structures. Cholinergic neurons are primarily affected, leading to a sharp decrease in acetylcholine concentration. The main pharmacological strategy is to compensate for this deficit using anticholinesterase agents.
Pharmacotherapy for dementia has evolved through several stages:
- Tacrine (Cognex): One of the first agents, now strictly limited in use due to severe hepatotoxicity and numerous adverse reactions.
- Modern generation: Galantamine (Razadyne), rivastigmine (Exelon), donepezil (Aricept).
Modern agents feature high selectivity. They inhibit acetylcholinesterase predominantly in brain tissues (especially rivastigmine), with minimal impact on the enzyme in skeletal muscle and internal organs. Consequently, they possess a more favorable safety profile: no hepatotoxicity and fewer peripheral effects.
Regimen:
- Donepezil is administered once daily.
- Galantamine and rivastigmine are administered twice daily.
- Rivastigmine is also available as a transdermal therapeutic system (patch) effective for 24 hours.
Such symptomatic therapy improves cognitive functions (memory, attention, speech) and partially mitigates the manifestations of dementia.
Characteristics of Galantamine and Ipidacrine
Galantamine (Nivalin) is a snowdrop alkaloid that has found wide application beyond dementia therapy. It is actively used in neurology to treat skeletal muscle paralysis (sequelae of poliomyelitis, spastic forms of cerebral palsy) and is administered subcutaneously for myasthenia gravis. In internal medicine, it helps manage bowel and bladder atony. In anesthesiology, it is administered intravenously as an effective antagonist of nondepolarizing neuromuscular blockers.
Ipidacrine (Neuromidin) features a unique dual mechanism:
- Exerts weak anticholinesterase activity.
- Blocks potassium channels on neuronal membranes, which facilitates depolarization and significantly improves nerve impulse conduction.
Ipidacrine acts in both the central and peripheral nervous systems. Its indications include polyneuritis, myasthenic crises, bulbar paralysis, bowel atony, and uterine inertia.
Toxicology and Side Effects
The effects of central nervous system-penetrating anticholinesterase drugs are strictly dose-dependent. While low doses provide a favorable stimulating effect (accelerating reflexes, improving attention), high doses lead to severe intoxication: generalized seizures progressing to coma, and fatal depression of the respiratory center.
Typical side effects include gastrointestinal disturbances (nausea, vomiting, diarrhea) and neurological symptoms (headache, dizziness).
Carbamate Poisoning (Agricultural Insecticides) Carbamates are readily absorbed through the skin and mucous membranes. The clinical presentation of intoxication is identical to organophosphate (OP) poisoning, but milder and resolves faster because cholinesterase inhibition is reversible.
Rescue Principles: Unlike organophosphate poisoning, cholinesterase reactivators are not used because they are unnecessary due to the short duration of binding between the poison and the enzyme. The primary emergency treatment is atropine, which competitively displaces excess acetylcholine from binding with muscarinic receptors.